Combining pathology artificial intelligence and genomic biomarkers to refine long-term postprostatectomy outcome prediction

2026-07-10

PRE

Matthew R Cooperberg, MD, MPH *

Kevin Shee, MD, Phd

Janet E Cowan, MA

Chien-Kuang C Ding, MD, PhD

Tamara Todorovic, BS, MPH

Imelda Tenggara, MS

Siyi Tang, PhD

Rikiya Yamashita, MD, PhD

Trevor Royce, MD, MPH

Emmalyn Chen, PhD

Meghan Tierney, RN, PhD

Xiao Ma, PhD

Yi Ren, MS

Huei-Chung Huang, MS

Danielle C Croucher, PhD

Jeffry P Simko, MD, MPH

Felix Y Feng, MD

Timothy Showalter, MD, MPH

Peter R Carroll, MD, MPH

DOI：10.1093/jnci/djag210

Original

Original request for help

Save

Abstract

En 中文

A multimodal AI (MMAI) model has been validated in prostate biopsy specimens to guide treatment intensification in men receiving radiation. The MMAI has been explored to an extent for prostatectomy patients and has not yet been examined in relation to established genomic scores.

Combining pathology artificial intelligence and genomic biomarkers to refine long-term postprostatectomy outcome prediction

Abstract

Journal

Organization

Cited Papers

Citing Papers